E
Eunice S. Wang
Researcher at Roswell Park Cancer Institute
Publications - 327
Citations - 8948
Eunice S. Wang is an academic researcher from Roswell Park Cancer Institute. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 39, co-authored 282 publications receiving 6683 citations. Previous affiliations of Eunice S. Wang include Geron Corporation & University at Buffalo.
Papers
More filters
Journal ArticleDOI
Acute myeloid leukemia, version 3.2017: Clinical practice guidelines in oncology
Margaret R. O'Donnell,Martin S. Tallman,Camille N. Abboud,Jessica K. Altman,Frederick R. Appelbaum,Daniel A. Arber,Vijaya Raj Bhatt,Dale L. Bixby,William Blum,Steven Coutre,Marcos de Lima,Amir T. Fathi,Melanie Fiorella,James M. Foran,Steven D. Gore,Aric C. Hall,Patricia Kropf,Jeffrey E. Lancet,Lori J. Maness,Guido Marcucci,Michael Gary Martin,Joseph O. Moore,Rebecca L. Olin,Deniz Peker,Daniel A. Pollyea,Keith W. Pratz,Farhad Ravandi,Paul J. Shami,Richard Stone,Stephen A. Strickland,Eunice S. Wang,Matthew J. Wieduwilt,Kristina M. Gregory,Ndiya Ogba +33 more
TL;DR: This portion of the NCCN Guidelines for AML focuses on management and provides recommendations on the workup, diagnostic evaluation, and treatment options for younger and older adult patients.
Journal ArticleDOI
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
Alexander E. Perl,Jessica K. Altman,Jorge E. Cortes,Catherine C. Smith,Mark R. Litzow,Maria R. Baer,David F. Claxton,Harry P. Erba,Stan Gill,Stuart L. Goldberg,Joseph G. Jurcic,Richard A. Larson,Chaofeng Liu,Ellen K. Ritchie,Gary J. Schiller,Alexander I. Spira,Stephen A. Strickland,Raoul Tibes,Raoul Tibes,Celalettin Ustun,Eunice S. Wang,Robert K. Stuart,Christoph Röllig,Andreas Neubauer,Giovanni Martinelli,Erkut Bahceci,Mark J. Levis +26 more
TL;DR: Gilteritinib was well tolerated in this heavily pretreated population; Grade 3 diarrhea and hepatic transaminase elevation limited dosing above 300 mg/d; response rate was improved in FLT3mut+ patients at doses ≥80mg/d.
Journal ArticleDOI
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark J. Levis,Farhad Ravandi,Eunice S. Wang,Maria R. Baer,Alexander E. Perl,Steven Coutre,Harry P. Erba,Robert K. Stuart,Michele Baccarani,Larry D. Cripe,Martin S. Tallman,Giovanna Meloni,Lucy A. Godley,Amelia Langston,Sergio Amadori,Ian D. Lewis,Arnon Nagler,Richard Stone,Karen W.L. Yee,Anjali S. Advani,Dan Douer,Wieslaw Wiktor-Jedrzejczak,Gunnar Juliusson,Mark R. Litzow,Stephen H. Petersdorf,Miguel A. Sanz,Hagop M. Kantarjian,Takashi Sato,Lothar Tremmel,Debra M. Bensen-Kennedy,Donald Small,B. Douglas Smith +31 more
TL;DR: Overall, lestaurtinib treatment after chemotherapy did not increase response rates or prolong survival of patients withFLT3 mutant acute myeloid leukemia in first relapse, and any conclusions regarding the efficacy of combining FLT3 inhibition with chemotherapy are limited.
Journal ArticleDOI
NCCN Clinical Practice Guidelines Acute myeloid leukemia.
M R O'Donnell,Camille N. Abboud,Jessica K. Altman,F R Appelbaum,Daniel A. Arber,Eyal C. Attar,Uma Borate,S. E. Coutre,Lloyd E. Damon,Salil Goorha,Jeffrey E. Lancet,Lori J. Maness,G. Marcucci,Michael Millenson,Joseph O. Moore,Farhad Ravandi,Paul J. Shami,B D Smith,Richard Stone,Stephen A. Strickland,Martin S. Tallman,Eunice S. Wang,Maoko Naganuma,Kristina M. Gregory +23 more
TL;DR: Challenges in the management of the adult with AML are discussed, including ongoing questions concerning the optimal choice of induction and postremission therapy such as the rationale for and role of allogeneic and autologous stem cell transplantation in a variety of settings, the special considerations pertaining to the older patient, and the development of new, so-called targeted therapies.
Journal ArticleDOI
Acute myeloid leukemia, version 3.2019
Martin S. Tallman,Eunice S. Wang,Jessica K. Altman,Frederick R. Appelbaum,Vijaya Raj Bhatt,Dale L. Bixby,Steven Coutre,Marcos de Lima,Amir T. Fathi,Melanie Fiorella,James M. Foran,Aric C. Hall,Meagan A. Jacoby,Jeffrey E. Lancet,Thomas W. LeBlanc,Gabriel N. Mannis,Guido Marcucci,Michael Gary Martin,Alice S. Mims,Margaret R. O'Donnell,Rebecca L. Olin,Deniz Peker,Alexander E. Perl,Daniel A. Pollyea,Keith W. Pratz,Thomas Prebet,Farhad Ravandi,Paul J. Shami,Richard Stone,Stephen A. Strickland,Matthew J. Wieduwilt,Kristina M. Gregory,Lydia J. Hammond,Ndiya Ogba +33 more
TL;DR: This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML focuses on the management of AML and provides recommendations on the workup, diagnostic evaluation and treatment options for younger and older adult patients.